Azelaic acid (15% gel) in the treatment of acne rosacea

International Journal of Dermatology

Volumn 46, Issue 5, 2007, Pages 533-538

  Gupta, Aditya K ^a,b,c   Gover, Melissa D ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; DICARBOXYLIC ACID DERIVATIVE; FINACEA; METRONIDAZOLE; UNCLASSIFIED DRUG;

ACNE; ALOPECIA; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHLOASMA; CLINICAL TRIAL; CREAM; DEPIGMENTATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; GEL; HERPES LABIALIS; HUMAN; HYPERTRICHOSIS; KERATINIZATION; MALIGNANT LENTIGO; MELANOMA; META ANALYSIS; MONOTHERAPY; PAPULE; PERIORAL DERMATITIS; PHOTOALLERGY; PHOTOTOXICITY; PRURITUS; PUSTULE; ROSACEA; SKIN BURNING SENSATION; SKIN DEFECT; SKIN IRRITATION; SKIN PENETRATION; SYSTEMATIC REVIEW; VITILIGO;

DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; GELS; HUMANS; OINTMENTS; RANDOMIZED CONTROLLED TRIALS; ROSACEA; TREATMENT OUTCOME;

EID: 34248164545     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2005.02769.x     Document Type: Article

References (41)

1. NDA Approvals for Calender Year 2002. http://www.fda.gov/cder/rdmt/ ndaaps02cy.htm. 10-14-2003.
2. Intendis, Inc. Finacea® (azelaic acid) Gel, 15% (package insert), 2005.
3. Murray L. SAE: Physicians' Desk Reference®, 57th edn. Montvale (NJ): Thomson PDR, 2003: 545 & 945.
4. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol 2003; 48: 836-845.
5. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: Results of a randomized trial. Arch Dermatol 2003; 139: 1444-1450.
6. Bjerke R, Fyrand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm Venereol 1999; 79: 456-459.
7. Carmichael AJ, Marks R, Graupe KA, et al. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat 1993; 4: S19-S22.
8. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999; 40: 961-965.
9. Bladon PT, Burke BM, Cunliffe WJ, et al. Topical azelaic acid and the treatment of acne: A clinical and laboratory comparison with oral tetracycline. Br J Dermatol 1986; 114: 493-499.
10. Cavicchini S, Caputo R. Long-term treatment of acne with 20% azelaic acid cream. Acta Derm Venereol Suppl (Stockh) 1989; 143: 40-44.
11. Cunliffe WJ, Holland KT. Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Derm Venereol Suppl (Stockh) 1989; 143: 31-34.
12. Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001; 11: 538-544.
13. Hjorth N, Graupe K. Azelaic acid for the treatment of acne. A clinical comparison with oral tetracycline. Acta Derm Venereol Suppl (Stockh) 1989; 143: 45-48.
14. Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989; 143: 35-39.
15. Nazzaro-Porro M, Passi S, Picardo M, et al. Beneficial effect of 15% azelaic acid cream on acne vulgaris. Br J Dermatol 1983; 109: 45-48.
16. Spellman MC, Pincus SH. Efficacy and safety of azelaic acid and glycolic acid combination therapy compared with tretinoin therapy for acne. Clin Ther 1998; 20: 711-721.
17. Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991; 30: 893-895.
18. Graupe K, Verallo-Rowell VM, Verallo V, et al. Combined use of 20% azelaic acid cream and 0.05% tretinoin cream in the topical treatment of melasma. J Dermatol Treat 1996; 7: 235-237.
19. Kakita LS, Lowe NJ. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: A clinical comparison with hydroquinone. Clin Ther 1998; 20: 960-970.
20. Lowe NJ, Rizk D, Grimes P, et al. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther 1998; 20: 945-959.
21. Sarkar R, Bhalla M, Kanwar AJ. A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology 2002; 205: 249-254.
22. Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh) 1989; 143: 58-61.
23. Nazzaro-Porro M, Passi S, Zina G, et al. Ten years' experience of treating lentigo maligna with topical azelaic acid. Acta Derm Venereol Suppl (Stockh) 1989; 143: 49-57.
24. Vereecken P, Heenen M. Recurrent lentigo maligna melanoma: Regression associated with local azelaic acid 20%. Int J Clin Pract 2002; 56: 68-69.
25. Nazzaro-Porro M, Passi S, Zina G, et al. Effect of azelaic acid on human malignant melanoma. Lancet 1980; 1: 1109-1111.
26. Jansen T. Azelaic acid as a new treatment for perioral dermatitis: results from an open study. Br J Dermatol 2004; 151: 933-934.
27. Stamatiadis D, Bulteau-Portois MC, Mowszowicz I. Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol 1988; 119: 627-632.
28. USP DI - Drug Information for the Health Care Professional. Thomson MICROMEDEX, 2004: 458-460.
29. Oztas MO, Balk M, Ogus E, et al. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol 2003; 28: 188-192.
30. Akamatsu H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: A possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res 1991; 283: 162-166.
31. Passi S, Picardo M, De Luca, C et al. Scavenging activity of azelaic acid on hydroxyl radicals "in vitro". Free Radic Res Commun 1991; 11: 329-338.
32. Jones D. Reactive oxygen species and rosacea. Cutis 2004; 74: S17-S20.
33. Akamatsu H, Horio T, Hattori K. Increased hydrogen peroxide generation by neutrophils from patients with acne inflammation. Int J Dermatol 2003; 42: 366-369.
34. Bojar RA, Holland KT, Leeming JP, et al. Azelaic acid: Its uptake and mode of action in Staphylococcus epidermidis NCTC 11047. J Appl Bacteriol 1988; 64: 497-504.
35. Bojar RA, Cunliffe WJ, Holland KT. Disruption of the transmembrane pH gradient - a possible mechanism for the antibacterial action of azelaic acid in Propionibacterium acnes and Staphylococcus epidermidis. J Antimicrob Chemother 1994; 34: 321-330.
36. Mayer-da Silva A, Gollnick H, Imcke E, et al. Azelaic acid vs. placebo: effects on normal human keratinocytes and melanocytes. Electron microscopic evaluation after long-term application in vivo. Acta Derm Venereol 1987; 67: 116-122.
37. Mayer-da-Silva A, Gollnick H, Detmar M, et al. Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin. An in vivo and in vitro study. Acta Derm Venereol Suppl (Stockh) 1989; 143: 20-30.
38. Schallreuter KU, Wood JW. A possible mechanism of action for azelaic acid in the human epidermis [abstract]. Arch Dermatol Res 1990; 282: 168-171.
39. Draelos ZD, Graupe K. A new topical formulation of mild to moderate papulopustular rosacea: Azelaic acid 15% gel. Poster presented at the American Academy of Dermatology 61st Annual Meeting 2003.
40. Gupta A, Chaudhry M. Rosacea and its management: An overview. J Eur Acad Dermatol Venereol 2005; 19: 273-285.
41. Draelos ZD. Noxious sensory perceptions in patients with mild to moderate rosacea treated with azelaic acid 15% gel. Cutis 2004; 74: 257-260.